202 related articles for article (PubMed ID: 36720762)
41. An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Kyritsis AP; Levin VA
Cancer Chemother Pharmacol; 2011 May; 67(5):971-83. PubMed ID: 21442438
[TBL] [Abstract][Full Text] [Related]
42. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW
J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052
[TBL] [Abstract][Full Text] [Related]
43. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y
Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771
[TBL] [Abstract][Full Text] [Related]
44. Radiosurgery and Stereotactic Brain Radiotherapy with Systemic Therapy in Recurrent High-Grade Gliomas: Is It Feasible? Therapeutic Strategies in Recurrent High-Grade Gliomas.
Gregucci F; Surgo A; Carbonara R; Laera L; Ciliberti MP; Gentile MA; Caliandro M; Sasso N; Bonaparte I; Fanelli V; Tortora R; Paulicelli E; Surico G; Lombardi G; Signorelli F; Fiorentino A
J Pers Med; 2022 Aug; 12(8):. PubMed ID: 36013284
[TBL] [Abstract][Full Text] [Related]
45. Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).
Navarria P; Minniti G; Clerici E; Tomatis S; Pinzi V; Ciammella P; Galaverni M; Amelio D; Scartoni D; Scoccianti S; Krengli M; Masini L; Draghini L; Maranzano E; Borzillo V; Muto P; Ferrarese F; Fariselli L; Livi L; Pasqualetti F; Fiorentino A; Alongi F; di Monale MB; Magrini S; Scorsetti M
J Neurooncol; 2019 Mar; 142(1):59-67. PubMed ID: 30515706
[TBL] [Abstract][Full Text] [Related]
46. Dabrafenib plus trametinib in patients with BRAF
Wen PY; Stein A; van den Bent M; De Greve J; Wick A; de Vos FYFL; von Bubnoff N; van Linde ME; Lai A; Prager GW; Campone M; Fasolo A; Lopez-Martin JA; Kim TM; Mason WP; Hofheinz RD; Blay JY; Cho DC; Gazzah A; Pouessel D; Yachnin J; Boran A; Burgess P; Ilankumaran P; Gasal E; Subbiah V
Lancet Oncol; 2022 Jan; 23(1):53-64. PubMed ID: 34838156
[TBL] [Abstract][Full Text] [Related]
47. Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH).
Benesch M; Wagner S; Berthold F; Wolff JE
J Neurooncol; 2005 Apr; 72(2):179-83. PubMed ID: 15925999
[TBL] [Abstract][Full Text] [Related]
48. Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Lu G; Zhu P; Rao M; Linendoll N; Buja LM; Bhattacharjee MB; Brown RE; Ballester LY; Tian X; Pilichowska M; Wu JK; Hergenroeder GW; Glass WF; Chen L; Zhang R; Pillai AK; Hunter RL; Zhu JJ
J Neurooncol; 2022 Oct; 160(1):221-231. PubMed ID: 36203027
[TBL] [Abstract][Full Text] [Related]
49. Low-grade gliomas.
Stieber VW
Curr Treat Options Oncol; 2001 Dec; 2(6):495-506. PubMed ID: 12057095
[TBL] [Abstract][Full Text] [Related]
50. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Verhoeff JJC; Lavini C; van Linde ME; Stalpers LJA; Majoie CBLM; Reijneveld JC; van Furth WR; Richel DJ
Ann Oncol; 2010 Aug; 21(8):1723-1727. PubMed ID: 20064829
[TBL] [Abstract][Full Text] [Related]
51. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
52. Current and promising treatment strategies in glioma.
Śledzińska P; Bebyn M; Furtak J; Koper A; Koper K
Rev Neurosci; 2023 Jul; 34(5):483-516. PubMed ID: 36062548
[TBL] [Abstract][Full Text] [Related]
53. Concurrent hyperthermia and re-irradiation for recurrent high-grade gliomas.
Heo J; Kim SH; Oh YT; Chun M; Noh OK
Neoplasma; 2017; 64(5):803-808. PubMed ID: 28592133
[TBL] [Abstract][Full Text] [Related]
54. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
55. A Retrospective Review of Re-irradiating Patients' Recurrent High-grade Gliomas.
Klobukowski L; Falkov A; Chelimo C; Fogh SE
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):563-570. PubMed ID: 29891395
[TBL] [Abstract][Full Text] [Related]
56. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study.
Sahebjam S; Forsyth PA; Tran ND; Arrington JA; Macaulay R; Etame AB; Walko CM; Boyle T; Peguero EN; Jaglal M; Mokhtari S; Enderling H; Raghunand N; Gatewood T; Long W; Dzierzeski JL; Evernden B; Robinson T; Wicklund MC; Kim S; Thompson ZJ; Chen DT; Chinnaiyan P; Yu HM
Neuro Oncol; 2021 Apr; 23(4):677-686. PubMed ID: 33173935
[TBL] [Abstract][Full Text] [Related]
57. Evolving management of low grade glioma: No consensus amongst treating clinicians.
Field KM; Rosenthal MA; Khasraw M; Sawkins K; Nowak AK
J Clin Neurosci; 2016 Jan; 23():81-87. PubMed ID: 26601811
[TBL] [Abstract][Full Text] [Related]
58. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY
J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064
[TBL] [Abstract][Full Text] [Related]
59. Irradiation and bevacizumab in high-grade glioma retreatment settings.
Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162
[TBL] [Abstract][Full Text] [Related]
60. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
